Comparision between Vamana Karma and Virechana Karma in Shwitra or Vitiligo.

Efficacy of Vamana & Virechana Karma followed by Kakodumbaradi Lepa & Vidangadi Churna in the management of Shwitra w.s.r to Vitiligo.-An Open Labelled Randomized Comparative Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/023750

Enrollment

Registered

2020-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Vamana Karma followed by Kakodumbaradi Lepa & Vidangadi Churna: In group A patient will undergo Deepana Pachana with Trikatu Churna 3 gms twice a day for 2-4 days followed by Snehpana

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having sign and symptoms of Shwitra (Vitiligo). 2.Patients indicated for Vamana and Virechana Karma as per Ayurvedic classics. 3.If the patients to withdrawn ongoing medications like systemic corticosteroids, systemic or local photosensitizers or drugs scientifically proven to cause hyperpigmentation on local application or systemic administration will be included. Washout period after quitting will be for 7 days. 4.Patient having chronicity less than or equal to 5 years .

Exclusion criteria

Exclusion criteria: 1.Patients having chronic condition, more than 5 years 2.Patients contraindicated for Vamana & Virechana Karma as per Ayurvedic Classics. 3.Patients having all other de-pigmentory disorders. 4.Patients having serious cardiac, renal, hepatic diseases. 5.Patients having major illness like Hypertension, Diabetes Type 1 & Type 2 which are poorly controlled and any other systemic diseases. 6.Patches due to burning, chemical explosion etc. 7.Located at region of Guhya (Genital region), Panitala (Foot soles and Hand soles), Oshtha (Lips), Sarvanga(whole body). 8.Patches with Raktaroma & Sansakta. 9.Patients with known drug hypersensitivity and photosensitivity. 10.Pregnant and lactating women. 11.Patient having age less than 18 and more than 60.

Design outcomes

Primary

Measure	Time frame
Relief in Sign and Symptoms of ShwitraTimepoint: Relief in Sign and Symptoms of Shwitra within 1 month of trial	—

Secondary

Measure	Time frame
Improvement in Quality of Life and Social Wellbeing of patientTimepoint: Improvement in Quality of Life and Social Wellbeing of patient within 1 year of trial	—

Countries

India

Contacts

Public ContactProf Dr Anup B Thakar

IPGT and RA GAU Jamnagar

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026